Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
1.
arxiv; 2023.
Preprint in English | PREPRINT-ARXIV | ID: ppzbmed-2311.06943v1

ABSTRACT

Nanobubbles and related technologies are expected to be highly utilized in water resource-based industries such as water purification, crops, horticulture, medicine, bio, and sterilization. Ozone, a chemical with high sterilizing power, is known as a natural substance that is reduced to oxygen and water after reacting with pollutants. Ozone water, which is generated by dissolving ozone in water, has been used in various industrial sectors such as medical care, food, and environment. Due to the unstable molecular state of ozone, however, it is difficult to produce, use, and supply ozone at industrial sites in a stable manner. This study proposed a method for constructing a system that can generate high-concentration ozone water in large quantities using low power in real time and maintaining the concentration of the generated ozone water over the long term. Friction tubes (called 'nanotube') played a key role to generate nanobubble ozone water with an increased half-life for virus killing activity. In addition, the safety of ozone water during its spray into the air was explained, and virucidal activity test cases for the influenza A (H1N1/A/PR8) and COVID-19 (SARS-CoV-2) virus using high-concentration ozone water as well as its technical efficacy were described.


Subject(s)
COVID-19
2.
ChiCTR; 2023-10-08; TrialID: ChiCTR2300076427
Clinical Trial Register | ICTRP | ID: ictrp-ChiCTR2300076427

ABSTRACT

Condition:

COVID-19

Intervention:

Ozone treatment group:Drug therapy was carried out according to the guidelines for the diagnosis and treatment of COVID-19+ Ozone autologous blood therapy;Control group:Drug therapy was carried out according to the guidelines for the diagnosis and treatment of COVID-19;

Primary outcome:

Inflammatory marker ;

Criteria:

Inclusion criteria: Age 18-80, male and female;
The diagnostic criteria for mild and medium novel coronavirus pneumonia in adults in the 10th Trial Edition of the 2023 Diagnosis and treatment plan are:1. Have clinical manifestations related to COVID-19 infection; 2. Have one or more of the following etiological and serological test results: (1) positive nucleic acid test of novel coronavirus; (2) positive antigen test of novel coronavirus; (3) Isolation and culture of the novel coronavirus are positive; (4) The level of novel coronavirus specific IgG antibody increased 4 times or more in the convalescent phase than in the acute phase. Clinical classification (1) Mild. The main manifestations were respiratory tract infection, such as dry throat, sore throat, cough, fever, etc. (2) medium-sized. Persistent high fever > 3 days or/and/or cough, shortness of breath, but RR < 30 beats/min, oxygen saturation > 93% when breathing at rest. Imaging shows the characteristic manifestations of COVID-19 pneumonia;
Patients who signed informed consent forms.

Exclusion criteria: Massive blood loss, acute bleeding, anemia (Hb<90g/L); Severe coagulopathy or thrombocytopenia less than 50X10^9/L; Thalassemia, sickle cell anemia, glucose-6-phosphate dehydrogenase deficiency (patients with faba disease); Toxic diffuse goiter (Graves' disease); Severe unstable cardiovascular disease, acute myocardial infarction; Women who are pregnant or lactating or menstruating in women; Patients with psychiatric, neurological conditions or hypersensitivity; Continuous use of immunosuppressants or organ transplantation within the past 6 months; Investigator-assessed participants who felt that they were unable or unwilling to adhere to the protocol requirements. Intestinal obstruction, intestinal perforation, acute alcohol poisoning.

3.
AIP Conference Proceedings ; 2674, 2023.
Article in English | Scopus | ID: covidwho-20242668

ABSTRACT

Disinfection of a room is very important to note, especially because of the presence of the coronavirus which has been confirmed to be able to spread through the air, stick to objects around it and has a high potential to transmit the virus. This is exacerbated by the presence of a new variant of the coronavirus which causes an increasing number of people to be exposed every day. One of the most effective disinfectants is ozone. Ozone is a gas formed from three oxygen atoms which is highly reactive and more unstable than oxygen. Ozone with the right concentration of about 1 ppm can kill pathogens, such as bacteria and viruses. This research focuses on designing an independent control and monitoring system based on Human Machine Interface (HMI). This control and monitoring system design can be applied to measure ozone concentration and is equipped with a timer and automatic mode. The test results obtained total accuracy value of this device with variables of voltage, current, generator temperature, ambient temperature in the box, humidity in the box, and ozone concentration is 97.3%, while total precision value is 98.5%. This research was conducted by testing the appliance in a 1.2 x 1.5 x 2.5 m room for 10 minutes and the results showed that the voltage used by the appliance is in the range of 216V to 219V with a current dropping from 0.56A to a stability point of 0.46A. The maximum temperature at the generator is around 96oC with an ambient temperature of 38oC, the humidity decreases from 81% to 68% and the ozone concentration produced can be stable around 1 ppm in 1 minute which can be used to kill bacteria and viruses. © 2023 American Institute of Physics Inc.. All rights reserved.

4.
Braz. J. Pharm. Sci. (Online) ; 58: e20775, 2022. tab, graf
Article in English | WHO COVID, LILACS (Americas) | ID: covidwho-20232559

ABSTRACT

Abstract Up to today, there is no specific treatment against SARS-CoV-2 / COVID-19 infection; there the necessity to search for alternatives that help patients with COVID-19. The objective of this study was to review the use of ozone therapy as adjunct treatment for SARS-CoV-2 / COVID-19 infection, highlighting the mechanisms of action, forms of application and current clinical evidence. A systematic review was conducted in electronic databases, searching the terminology Ozone "or" Ozone therapy "and" SARS-CoV-2 or COVID-19 or Coronavirus. Results: nineteen studies were included; ten were editorials, comments, brief reports or reviews, and nine clinical studies. We found that ozone therapy could be favorable for treating patients infected with SARS-CoV-2 / COVID-19, through a direct antiviral effect, regulation of oxidative stress, immunomodulation and improvement of oxygen metabolism. Patients who were treated with ozone therapy responded favorably; therefore, ozone therapy appears to be a promising treatment for patients infected with SARS-CoV-2 / COVID-19. Its mechanism of action justifies its use as an adjuvant therapy; however, scientific evidence is based on case series and clinical trials are necessary to corroborate its effectiveness and safety.


Subject(s)
Coronavirus/pathogenicity , SARS-CoV-2/classification , COVID-19/pathology , Ozone Therapy , Antiviral Agents/analysis , Patients/classification , Oxidative Stress , Research Report , Infections/classification
5.
Journal of Kerman University of Medical Sciences ; 30(2):92-99, 2023.
Article in English | EMBASE | ID: covidwho-2323820

ABSTRACT

Background: There is still no specific treatment strategy for COVID-19 other than supportive management. The potential biological benefits of ozone therapy include reduced tissue hypoxia, decreased hypercoagulability, modulated immune function by inhibiting inflammatory mediators, improved phagocytic function, and impaired viral replication. This study aimed to evaluate the effect of intravenous ozonated normal saline on patients with severe COVID-19 disease. Method(s): In this study, a single centralized randomized clinical trial was conducted on 80 hospitalized patients with severe COVID-19. The patients were selected by random allocation method and divided into two groups A and B. In group A (control group), patients were given standard drug treatment, and in group B (intervention group), patients received ozonated normal saline in addition to the standard drug treatment. In the intervention group, 400 mL of normal saline was weighed by 40 mug/ kg of body weight and was injected into patients within 15 to 30 minutes (80 to 120 drops per minute). This process was done daily every morning for a week. Primary and secondary outcomes of the disease included changes in the following items: length of hospital stay, inflammatory markers including C-reactive protein (CRP), clinical recovery, arterial blood oxygen status, improvement of blood disorders such as leukopenia and leukocytosis, duration of ventilator attachment, and rapid clearance of lung lesions on CT scans. The need for intensive care unit (ICU) hospitalization, the length of ICU stay, and the mortality rate in patients of the two groups was compared. Result(s): According to the results of the initial outcome variable analysis, the probability of discharge of patients who received the normal ozonated saline intervention was 33% higher than patients who did not receive this intervention;however, this relationship was not statistically significant (HR = 0.67, 95%, CI = 0.42-1.06, P value = 0.089). The chance of ICU hospitalization in patients of the intervention group was three times more than that of the comparison group, but this relationship was not significant (odds ratio = 4.4 95% CI = 1.32-14.50, P value = 0.016). The use of ozonated normal saline was found to increase the risk of death by 1.5 times but this relationship was not statistically significant (odds ratio = 1.5, 95% CI = .24-9.75, P value = 0.646). Ozonated normal saline had a significant effect on changes in respiration rate (in the intervention group the number of breaths was decreased) and the erythrocyte sedimentation rate (in the intervention group the erythrocyte sedimentation rate was increased);however, it had no significant effect on other indicators. Conclusion(s): The present study showed that ozone therapy in hospitalized patients with severe COVID-19 could help improve some primary and secondary outcomes of the disease. Governments and health policymakers should make ozone therapy an available care service so that the need for advanced treatment facilities decreases;consequently, this measure may improve patient safety, prevent lung tissue destruction, and control cytokine storms in patients. Additionally, health decision-makers need to aim for the effective clinical improvement of patients, especially severe ones, and the reduction of their mortality. However, further large-scale multicenter studies with larger sample sizes considering drug side effects and other variables influencing the clinical course of COVID-19 can provide more information on the effectiveness and importance of ozone therapy.Copyright © 2023 The Author(s);Published by Kerman University of Medical Sciences.

6.
Encyclopedia of Infection and Immunity ; 4:702-712, 2022.
Article in English | Scopus | ID: covidwho-2302779

ABSTRACT

Nonpharmacological approaches can be useful to control infectious diseases. Historically infection has been successfully managed with oxidation therapy methods that support the body's own innate defenses. Several modalities include ozone and hyperbaric oxygen therapy, ultraviolet blood irradiation (UBI), intravenous hydrogen peroxide, and ascorbate therapies. Oxidation therapies are virtually 100% safe, and repeatedly reported as highly and quickly effective in quelling infection (bacterial and viral) either as stand-alone therapies or adjunctive with drugs. They are directly and indirectly germicidal, and modulate the immune system via pro-oxidant signaling molecules. Oxidation therapies especially enhance oxygen delivery and metabolism, critical for all infection defenses. Ozone has remitted Ebola, COVID-19, and bacterial infections. UBI defeated most preantibiotic era infections in hospitals. Not being drug therapy, the effects of oxidation defenses, used by planetary animal life for millions of years, are not diminished by antibiotic-resistant organisms. Oxidation, depending on delivery method, can be very inexpensive and third world adaptable. This chapter summarizes the use of these key modalities, by exploring known published literature. © 2022 Elsevier Inc. All rights reserved.

7.
Photodiagnosis and Photodynamic Therapy ; Conference: ABSTRACTS of the Nancy Meeting 2022. Nancy France. 41 (no pagination), 2023.
Article in English | EMBASE | ID: covidwho-2296899

ABSTRACT

The Covid-19 epidemic has been the most consequential global health crisis since the era of the influenza pandemic of 1918 [1]. Due to its high spreading rate, the virus disseminated across the world in a very short time span, forcing the World Health Organization to declare Covid-19 a global pandemic after just 3 months from the first reported case in China. At the beginning of the pandemic, when no vaccines were available, people entrust their safety to very few devices such as personal protective equipment (face masks, shields, and gloves), lock-down, and social distancing. The lack of alternative and not conventional techniques to suppress the spread of airborne epidemics among humans has pushed the research to develop new antiviral devices. The SAVE-US project (Suppression of Airborne Viral Epidemic Spread by UV-Light Barriers) aims at developing and demonstrating an innovative antimicrobial device based on 222nm-radiation. As known from the literature, the UVC radiation (200-280 nm) is the most effective wavelength for the inactivation of viruses and bacteria, corresponding to the DNA and RNA absorption peaks, but may also be mutagenic. For this reason, UVC-light sterilization is commonly performed in the absence of living organisms. Radiation in the far-UVC, especially at 222 nm, has been recently investigated because it shows a good antimicrobial efficacy, tested already on both bacteria [2] and virus [3] models including coronavirus, with very limited risks to human health. The low risk is associated to the small penetration depth of 222 nm light (a few mum): the energy is absorbed by the superficial stratum corneum of the skin that contains dead cells, with negligible irradiation of the underlying live tissue [4]. We will present the first version of a new prototype of 222 nm-illuminator and some preliminary results on its characterization;the presented device will be used in successive in vitro and in vivo experiments with SARS-CoV-2 virus. The device embeds a far-UVC lamp emitting at 222 nm, optical filters, and the controlling electronics. We show results on the spatial homogeneity of the emission intensity and the dependence on the lamp-virus distance. We also report on the ozone production due to absorption of far-UVC light from molecular oxygen naturally present in the air in order to evaluate its safety for human being and to properly evaluate its photo-killing efficacy.Copyright © 2023

8.
Med Gas Res ; 13(4): 172-180, 2023.
Article in English | MEDLINE | ID: covidwho-2303413

ABSTRACT

Ozone therapy (OT), a medical procedure, has been showing good results during the coronavirus disease (COVID-19). We aimed to build an evidence and gaps map (EGM) of OT in the COVID-19 ranking the articles found according to levels of evidence and outcomes. The EGM brings bubbles of different sizes and different colors according to the articles. The OT intervention used was major or minor autohemotherapy, rectal insufflation and ozonized saline solution. EGM was based on 13 clinical studies using OT for COVID-19 involving a total of 271 patients. We found 30 outcomes related to OT in COVID-19. Our EGM divided the outcomes into six groups: 1-clinical improvement; 2-hospitalization; 3-inflammatory, thromboembolic, infectious, or metabolic markers; 4-radiological aspects, 5-viral infection and 6-adverse events. Major autohemotherapy was present in 19 outcomes, followed by rectal insufflation. Improvement in clinical symptoms of COVID-19, improvement of respiratory function, improvement of oxygen saturation, reduction in hospital internment, decrease in C-reactive protein, decrease in ferritin, decrease in lactate dehydrogenase, decrease in interleukin 6, decrease in D-dimer, radiological improvement of lung lesions and absence of reported adverse events were related in the papers. The most commonly used concentrations of OT in major autohemotherapy and in rectal insufflation were 40 µg/mL and 35 µg/mL, respectively. Here, we bring the first EGM showing the efficacy and safety of OT in the treatment of COVID-19. OT can be used as integrative medical therapy in COVID-19 at a low cost and improve the health conditions of the patients.


Subject(s)
COVID-19 , Ozone , Humans , COVID-19/therapy , SARS-CoV-2 , Ozone/therapeutic use , Treatment Outcome , Hospitalization
9.
Qeios ; 2021.
Article in English | EuropePMC | ID: covidwho-2267438

ABSTRACT

Almost all the countries around the world are experiencing high levels of air pollution. How does pollution impact our body in times of COVID-19? Air pollution and related climatic-environmental changes is one of the prime concern and biggest challenge globally in 21st century faced by most of the nations. The global impact of this public health problem can be assessed and understood from the data of morbidity and mortality as well as DALY (disability adjusted life years) & QALY (quality adjusted life years), YLL (years of life lost) measurements. Today global air is having several varieties and types of air pollutants which are taking lives of people on daily basis and the death count may be more as compared to covid-19 deaths. The finest and smallest particulate matters present in air as byproducts of several human and industry related activities are able to infiltrate the respiratory system through inhalation while breathing, leading to respiratory and cardiovascular system(CVS) diseases, reproductive and central nervous system(CNS) diseases and malfunctioning as well as various carcinoma. Ozone (O3) protects us from harmful effects of UV (ultra violet) radiations which can cause cancers, skin diseases as well as mutations etc but at the same time it is harmful when in high concentration at ground level, affecting the respiratory and cardiovascular system. Added to this other pollutants present in air such as nitrogen oxide(NO), sulfur dioxide(SO2), Volatile Organic Compounds (VOCs), dioxins, and polycyclic aromatic hydrocarbons (PAHs) are all important air pollutants which are known to be harmful to human beings. Carbon monoxide (CO) can bind with haemoglobin (Hb) very tightly (not allowing oxygen to be released at tissue level causing tissue hypoxia) forming carboxy-haemoglobin which can cause poisoning when breathed in at high levels. Heavy metals for example lead (Pb) can lead to direct poisoning (plumbinism or saturnism) or chronic intoxication can lead to a variety of CNS, GIT(gastrointestinal tract), and reproductive system diseases, depending on the exposure. Air pollution usually causes respiratory problems such as Chronic Obstructive Pulmonary Disease (COPD), asthma, bronchiolitis, lung cancer, cardiovascular events, central nervous system dysfunctions, and cutaneous diseases. Added to this, the climate change resulting from environmental pollution affects the geographical distribution of many infectious diseases like natural disasters as well as affects social and environmental determinants of health. The only way to tackle this problem is through public health awareness, strategies to reduce air pollution as well as environmental protection measures with a multidisciplinary Intersectoral approach by scientific experts of national and international organizations. The global leaders must address the emergence of this threat and propose sustainable and suitable solutions to deal this challenging issue. KEYWORDS: Covid-19, air pollution, environment, health, disease, policy, pollutant, public health

10.
Photodiagnosis and photodynamic therapy ; 41:103454-103454, 2023.
Article in English | EuropePMC | ID: covidwho-2263955

ABSTRACT

The Covid-19 epidemic has been the most consequential global health crisis since the era of the influenza pandemic of 1918 [1]. Due to its high spreading rate, the virus disseminated across the world in a very short time span, forcing the World Health Organization to declare Covid-19 a global pandemic after just 3 months from the first reported case in China. At the beginning of the pandemic, when no vaccines were available, people entrust their safety to very few devices such as personal protective equipment (face masks, shields, and gloves), lock-down, and social distancing. The lack of alternative and not conventional techniques to suppress the spread of airborne epidemics among humans has pushed the research to develop new antiviral devices. The SAVE-US project (Suppression of Airborne Viral Epidemic Spread by UV-Light Barriers) aims at developing and demonstrating an innovative antimicrobial device based on 222nm-radiation. As known from the literature, the UVC radiation (200-280 nm) is the most effective wavelength for the inactivation of viruses and bacteria, corresponding to the DNA and RNA absorption peaks, but may also be mutagenic. For this reason, UVC-light sterilization is commonly performed in the absence of living organisms. Radiation in the far-UVC, especially at 222 nm, has been recently investigated because it shows a good antimicrobial efficacy, tested already on both bacteria [2] and virus [3] models including coronavirus, with very limited risks to human health. The low risk is associated to the small penetration depth of 222 nm light (a few μm): the energy is absorbed by the superficial stratum corneum of the skin that contains dead cells, with negligible irradiation of the underlying live tissue [4]. We will present the first version of a new prototype of 222 nm-illuminator and some preliminary results on its characterization;the presented device will be used in successive in vitro and in vivo experiments with SARS-CoV-2 virus. The device embeds a far-UVC lamp emitting at 222 nm, optical filters, and the controlling electronics. We show results on the spatial homogeneity of the emission intensity and the dependence on the lamp-virus distance. We also report on the ozone production due to absorption of far-UVC light from molecular oxygen naturally present in the air in order to evaluate its safety for human being and to properly evaluate its photo-killing efficacy.

11.
Acta Veterinaria Brasilica ; 16(4):294-304, 2022.
Article in English | Scopus | ID: covidwho-2282928

ABSTRACT

Ozone therapy application and research have increased recently. The mixture of oxygen-ozone (O2-O3) has been used as a therapeutic agent for the treatment of several diseases with beneficial effects. This brief literature review has the objective of disclosing the mechanisms of action and main clinical indications and possibilities of ozone therapy for different conditions. The local and systemic approaches and techniques described for human treatment can be easily transposed for use in animals, such as rectal insufflation;bag therapy;ozonated oil;intradiscal and paravertebral applications;in acupuncture points;minor autohemotherapy, and major autohemotherapy. The possibilities of clinical indications and dosages were also described, including immunological and infectious diseases. Although it is a minimally invasive and relatively safe approach, more clinical studies are necessary to standardize techniques, doses, and clinical indications. © 2022 Universidade Federal Rural do Semi-Árido.

12.
J Intensive Med ; 1(2): 99-102, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-2286158

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) pandemic is a worldwide catastrophe, thoroughly challenging the healthcare systems. A growing number of victims suffer from a remarkable acute respiratory distress syndrome (ARDS) that necessitates admission to the intensive care unit (ICU), but there are no satisfactory treatments. Various gas therapies including nitric oxide, ozone, hyperbaric oxygen, hydrogen, and heliox have been employed in the fight against the pandemic and have improved clinical outcomes. However, the potential roles of these gases in COVID-19 treatment need to be verified in well-designed randomized controlled trials. This paper reviews advances in gaseous therapy of COVID-19.

13.
ClinicalTrials.gov; 03/03/2023; TrialID: NCT05773001
Clinical Trial Register | ICTRP | ID: ictrp-NCT05773001

ABSTRACT

Condition:

SARS-CoV-2 Pneumonia

Intervention:

Drug: Ozone

Primary outcome:

Change in the abundance of monocyte-derived alveolar macrophages

Criteria:


Inclusion Criteria:

- Individuals between 18-55 yrs. of age (No subject will be excluded from the study on
the basis of gender or ethnicity)

- Individuals with knowledge of prior SARS-CoV-2 infection history allowing them to be
segregated into one of three cohorts

- Cohort 1 - No history of SARS-CoV-2 infection (defined as no symptoms consisted
with SARS-CoV-2 nor history of a positive SARS-CoV-2 test)

- Cohort 2 - Documented mild SARS-CoV-2 infection (a positive test, either PCR- or
antigen-based) but with mild to no symptoms and no evidence of a lower
respiratory tract infection (including no hospitalization, and no oxygen use)

- Cohort 3 - History of SARS-CoV-2 infection and symptoms/imaging consistent with a
lower respiratory tract infection who have recovered, are >6 months out from
their infection, and have normal lung function (spirometry with FVC, FEV1 and
FEV1/FVC)

- There will be no maximal period from SARS-CoV-2 infection for inclusion in
the study, the minimal period will be >6 months out from infection

Exclusion Criteria:

- Individuals with prior SARS-CoV-2 pneumonia who have ongoing respiratory symptoms, are
still using supplemental oxygen, or have abnormal lung function

- Individuals with prior SARS-CoV-2 infection that cannot provide documentation of a
positive test

- Current smokers of tobacco products including e-cigarettes or those with previous
smoking history within the prior 5 years

- Pregnant women and women who are presently lactating.

- Subjects that have received antibiotic administration or an upper respiratory
infection within the previous 4 weeks

- College and graduate students or employees who are under direct supervision by any of
the investigators in this protocol

- Alcohol or illicit substance abuse

- Chronic cardio/pulmonary respiratory disorders or other medical conditions as
determined by the investigator

- Increased airway hyperresponsiveness at baseline as measured by a positive
methacholine challenge response (methacholine PC20 FEV1 < 4 mg/ml)

- Subjects will be requested to refrain from antihistamines, nonsteroidal
anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and
supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.


14.
27th Summer School Francesco Turco, 2022 ; 2022.
Article in English | Scopus | ID: covidwho-2147518

ABSTRACT

Thanks to the principles and technologies made available by Industry 4.0, the authors conceptualized and modeled a new strategy, capable of making an effective contribution to the problem of limiting contagion from Covid19 today, and tomorrow from any possible other type virus, bacteria or pathogen agent introduced by subjects who, although unaware of being vectors, develop the infection only after their access to the places of stay (Hotel, office, Infrastructure, etc.) where they go to reside. The key point of the strategy is a 4.0 thermoscanner, created by the authors, which is positioned in appropriately chosen locations of the settlement and an innovative method of disinfection of the same implemented by means of UV-C rays and Ozone in the gaseous state, produced by a machine, also conceptualized and developed by the authors, capable of reproducing the Chapman Cycle with the associated advantages. Therefore, it is operated an absolute disinfection based on a reversible cycle Oxygen-Ozone-Oxygen, with a prompt re-habitability of the treated rooms, with minimal treatment costs and without the use of expensive and unhealthy chemicals or wet water vapor (incompatible with paper and electronics). This technology was described in the paper “Sanitizing of Confined Spaces Using Gaseous Ozone Produced by 4.0 Machines” presented by the authors to the WCE 2021 IAENG Congress and awarded with the “Best Paper Award of the 2021 International Conference of Systems Biology and Bioengineering”. In the presence of a Person with a fever, the thermoscanner automatically launches an alert to the site Safety officers, who confine him to an isolated place and make the Health Institutions intervene and take it over. © 2022, AIDI - Italian Association of Industrial Operations Professors. All rights reserved.

15.
Complement Ther Med ; 72: 102907, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2149611

ABSTRACT

BACKGROUND: The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in the treatment of a variety of infectious diseases, probably through its antioxidant properties and the supply of oxygen to hypoxic tissues. This systematic review and meta-analysis aimed to determine the efficacy of ozone on mortality in patients with COVID-19. METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Prospective controlled trials on treatment of COVID-19 with ozone, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs) and weighted mean differences (WMDs), with 95% confidence intervals (CIs). RESULTS: Eight trials (enrolling 371 participants) met the inclusion criteria. Ozone therapy showed significant effects on mortality (RR 0.38, 95% CI 0.17-0.85; P = 0.02), length of hospital stay (WMD -1.63 days, 95% CI -3.05 to -0.22 days; P = 0.02), and polymerase chain reaction (PCR) positivity (RR 0.07, 95% CI 0.01-0.34; P = 0.001). CONCLUSIONS: Ozone therapy significantly reduced mortality, PCR positivity, and length of stay in hospitalized patients with COVID-19. Ozone therapy should be considered for COVID-19 patients.


Subject(s)
COVID-19 , Ozone , Humans , Ozone/therapeutic use , Prospective Studies , Antioxidants
16.
ClinicalTrials.gov; 16/12/2022; TrialID: NCT05680831
Clinical Trial Register | ICTRP | ID: ictrp-NCT05680831

ABSTRACT

Condition:

Lung Injury, Acute;Symptoms and Signs;Neutrophilia Acute

Intervention:

Biological: 0.070 ppm ozone concentration;Biological: Clean air (0.0 ppm ozone)

Primary outcome:

FVC;Change in FVC;FEV1;Change in FEV1

Criteria:


Inclusion Criteria:

1. Healthy men and women between 18 and 35 years of age.

2. Physical conditions allowing sustained moderate exercise for 6.6 hours.

3. Normal lung function (NHANES III):

1. FVC > 80 % of that predicted for gender, ethnicity, age and height.

2. FEV1 > 80 % of that predicted for gender, ethnicity, age and height.

3. FEV1/FVC ratio > 80 % of predicted values

4. Oxygen saturation > 94 %.

5. Total symptom Score no greater than 20 (out of a possible 60-see accompanying score
sheet) with a value no greater than 3 for any one score. No more than one score may be
equal to 3.

Exclusion Criteria:

1. Individuals with a diagnosis of COVID-19 and/or hospitalized for COVID-19.

2. Individuals who are not "up to date," [meaning a person has received all recommended
COVID-19 vaccines, including any booster dose(s) when eligible with their COVID
vaccines as defined by the CDC.]

3. A history of acute and chronic cardiovascular disease, chronic respiratory disease,
diabetes,rheumatologic diseases, immunodeficiency state.

4. An acute respiratory illness within 4 weeks.

5. Subjects who are asthmatic or have a history of asthma.

6. Allergic to chemical vapors or gases.

7. Any allergic symptoms during the time of participation in the study

8. Female subjects who are currently pregnant, attempting to become pregnant or
breastfeeding

9. Subjects currently taking mega doses of vitamins and supplements,
homeopathic/naturopathic medicines or medications which may impact the results of the
ozone challenge or interfere with any other medications potentially used in the study
(to include systemic steroids and beta blockers). Medications not specifically
mentioned here may be reviewed by the investigators prior to a subject's inclusion in
the study.

10. Current and past smokers within 2 years, or subjects with a smoking history of at
least a pack of cigarettes a day for more than 10 years over your lifetime. This
includes vaping, hookah,and e-cigarettes.

11. Uncontrolled hypertension (> 140 systolic, > 90 diastolic). Blood pressure readings
equal to or greater that 140 Systolic and equal to or greater that 90 diastolic.

12. Subjects who do not understand or speak English

13. Unspecified illnesses, which in the judgment of the investigator might increase the
risk associated with ozone inhalation challenge or exercise, will be a basis for
exclusion.

Temporary exclusion criteria:

1. Individuals who have had an acute respiratory illness within 4 weeks.

2. Individuals who have active allergies.

3. Individuals that have engaged in strenuous exercise within 24 hours of any study
visit.

4. Individuals unable to avoid drinking alcohol for 24 hours prior to all study visits.

5. Individuals who have been exposed to smoke and fumes for 24 hours before all visits.

6. Individuals that have used an ozone-based home air purifier for 24 hours before all
visits.

7. Individuals that have eaten or drank anything for 2 hours prior to the sputum
training/screening day visit.

8. Individuals should avoid caffeine for 12 hours prior to all study visits.

9. Individuals should refrain from all over the counter anti-inflammatory agents
including those for allergies, and anti-inflammatory drugs or antioxidants for a
period of one week prior to the train and to the exposure.

10. Individuals that have been exposed to or have consumed any agent or have undertaken
any activity within 24 hours of any study visit that the investigators believe may
compromise the results of the study.

-


17.
ACS Applied Polymer Materials ; 2022.
Article in English | Web of Science | ID: covidwho-2096627

ABSTRACT

Surface dielectric barrier discharge (SDBD) was used to inactivate the infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trapped in a polypropylene (PP) melt-blown filter. We used a dielectric barrier made of polyimide films with hexagonal holes through which air flowed. In a cylindrical wind tunnel, the SDBD device supplied reactive oxygen species such as ozone to the SARS-CoV-2 trapped in the PP filter. A plaque assay showed that SDBD at an ozone concentration of approximately 51.6 ppm and exposure time of 30 min induced more than 99.78% reduction for filter-adhered SARS-CoV-2. A carbon catalyst after SDBD effectively reduced ozone exhaust below 0.05 ppm. The combination of SDBD, PP filter, and catalyst could be a promising way to decrease the risk of secondary infection due to indoor air purifiers.

18.
Surface Engineering and Applied Electrochemistry ; 58(5):523-539, 2022.
Article in English | EuropePMC | ID: covidwho-2092254

ABSTRACT

Modern civilization, providing economic and social progress, at the same time objectively creates—sometimes close to ideal—conditions for the spread of various infections. The catastrophic consequences of the SARS-CoV-2 pandemic clearly indicate that homo sapiens appeared to be unable to effectively resist the onslaught of the coronavirus. The purpose of this publication is an attempt to fill the gap in the development of effective methods and means for microbiological decontamination that are optimal in terms of critical parameters. The observational data indicate that a significant number of SARS-CoV-2 coronavirus infections occur by air without a direct contact with the source, including over a long time interval. Precipitation helps to cleanse the air from pollutants and viruses, reducing noncontact contamination, which additionally brings up to date the problem of optimal microbiological decontamination of the air environment and surfaces. A thermodynamic approach has been used to optimize microbiological sterilization. It is shown that irreversible chemical oxidation reactions are the shortest way to achieve sterility, and they are capable of providing high reliability of decontamination. It has been established that oxygen is an optimal oxidant, including from the point of view of ecology, since its reactive forms harmoniously fit into natural exchange cycles. The optimal method for obtaining reactive oxygen species for disinfection is the use of low-temperature (“cold”) plasma, which provides the energy-efficient generation of oxidative reactive forms: atomic oxygen (O), ozone (O3), hydroxyl radical (•OH), hydrogen peroxide (H2O2), superoxide (

19.
Biomedicines ; 10(9)2022 Sep 12.
Article in English | MEDLINE | ID: covidwho-2032842

ABSTRACT

An increasing body of evidence in the literature is reporting the feasibility of using medical ozone as a possible alternative and adjuvant treatment for COVID-19 patients, significantly reducing hospitalization time, pro-inflammatory indicators, and coagulation markers and improving blood oxygenation parameters. In addition to the well-described ability of medical ozone in counteracting oxidative stress through the upregulation of the main anti-oxidant and scavenging enzymes, oxygen-ozone (O2-O3) therapy has also proved effective in reducing chronic inflammation and the occurrence of immune thrombosis, two key players involved in COVID-19 exacerbation and severity. As chronic inflammation and oxidative stress are also reported to be among the main drivers of the long sequelae of SARS-CoV2 infection, a rising number of studies is investigating the potential of O2-O3 therapy to reduce and/or prevent the wide range of post-COVID (or PASC)-related disorders. This narrative review aims to describe the molecular mechanisms through which medical ozone acts, to summarize the clinical evidence on the use of O2-O3 therapy as an alternative and adjuvant COVID-19 treatment, and to discuss the emerging potential of this approach in the context of PASC symptoms, thus offering new insights into effective and safe nonantiviral therapies for the fighting of this devastating pandemic.

20.
Vopr Kurortol Fizioter Lech Fiz Kult ; 99(4. Vyp. 2): 22-29, 2022.
Article in Russian | MEDLINE | ID: covidwho-2025845

ABSTRACT

OBJECTIVE: To evaluate the effectiveness and safety of ozone therapy in rehabilitation of patients with previous COVID-19. MATERIAL AND METHODS: A randomized controlled clinical trial included 51 patients aged 29 - 78 years with SARS-CoV-2 pneumonia (J12.8). Patients were divided into 3 comparable groups depending on the complex of rehabilitation. In the first (control) group (n=17), a 10-day course included daily breathing exercises and physiotherapy for the lungs (drug electrophoresis and low-frequency magnetotherapy). In the second (main) group (n=18), rehabilitation was combined with daily intravenous infusions of ozonized saline with ozone concentration of 2.0 mg/l within 5 days with subsequent standard rehabilitation. In the third group (n=16), patients received 5 ozone therapy procedures every other day. To determine the effectiveness and safety of systemic ozone therapy in rehabilitation of patients with previous COVID-19, we analyzed oxygen saturation, laboratory data (D-dimer and C-reactive protein), need for oxygen support before and after rehabilitation course. Complaints and quality of life throughout the rehabilitation program were assessed using the EQ-5D questionnaire. RESULTS: All patients had positive changes of all parameters. There were no adverse reactions throughout the rehabilitation program and 2 months later. We observed higher effectiveness of rehabilitation with systemic ozone therapy. Moreover, daily ozone therapy had a better effect on laboratory parameters compared to ozone therapy every other day. CONCLUSION: Ozone therapy is safe and effective in complex rehabilitation of patients with previous COVID-19. Further studies of large samples are needed to determine indications and appropriate criteria for this rehabilitation program.


Subject(s)
COVID-19 , Ozone , Humans , Lung , Ozone/therapeutic use , Quality of Life , SARS-CoV-2 , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL